 Cellectar Biosciences Inc NASDAQ:CLRB Analysts at Oppenheimer issued their Q2 2020 earnings per share estimates for Cellectar Biosciences in a research report issued on Wednesday, July 1st. Oppenheimer analyst K. Degeeter expects that the biopharmaceutical company will earn 0.27 per share for the quarter. Oppenheimer has a Outperform rating and a 5.00 price objective ... 